LIBRIUM
LOE ApproachingNDAINJECTIONINJECTABLE
Approved
Jul 1961
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
1
Data completeness
2/8 — Basic
Drug data last refreshed 3d ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
LIBRIUM (chlordiazepoxide) is an injectable benzodiazepine approved in 1961 for acute anxiety and alcohol withdrawal management. The drug works by enhancing GABA receptor activity in the central nervous system to reduce neuronal excitability. It is administered via intramuscular or intravenous injection for rapid symptom relief in acute clinical settings.
LOE Approaching
As a legacy product approaching loss of exclusivity with moderate competitive pressure (30%), the brand team is likely focused on cost management and institutional relationships rather than growth initiatives.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (1)
Carbetocin Trial: Carbetocin Appropriate Rate Better Equilibrium Between Tonus (TOnus) and CIrculatioN
Started Aug 2014
140 enrolled
Complications; Cesarean SectionAnesthesia; Reaction
Career Relevance
LIBRIUM offers limited career momentum given its legacy status, approaching LOE, and minimal job availability (0 linked positions). Roles on this product focus on defending institutional market share, managing price erosion, and maintaining healthcare provider relationships in acute care settings rather than driving growth or innovation.
Brand Manager
Worked on LIBRIUM at Bausch + Lomb? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.